Clinical Trial Update: Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Xevinapant added to standard radiation therapy plus cisplatin/carboplatin for head and neck cancers has been withdrawn. The study cover…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma of the Head and Neck
• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Lip and Oral Cavity Cancer
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Xevinapant (Xevinapant)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Status: WITHDRAWN